Tucidinostat plus CHOP for newly diagnosed PTCL-TFH lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new drug (tucidinostat) added to standard chemotherapy (CHOP) for people newly diagnosed with a specific type of lymphoma called PTCL-TFH. It aims to see if the combination works better than standard treatment alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old
- You have been diagnosed with a type of T-cell lymphoma called PTCL with follicular helper T-cell phenotype
- You have not had any previous treatment for your lymphoma
- You have at least one tumor that can be measured on scans
- Your blood counts and liver/kidney function are within certain ranges
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests linperlisib (a medicine that targets a cell-growth pathway) together with CHOP chemotherapy in people with peripheral T-cell lymphoma that has not been treated before. It may help shrink the lymphoma and control the disease by combining two approaches.
This trial tests a new drug, BEBT-908, combined with standard chemotherapy for people newly diagnosed with peripheral T-cell lymphoma (a type of blood cancer). The goal is to see if this combination helps control the cancer better.
This trial tests a new oral medication called golidocitinib for people who have just been diagnosed with a specific type of T-cell lymphoma and have not had any prior treatment. The goal is to see if this JAK1 inhibitor can help control the disease.
This trial tests a combination of a targeted drug (golidocitinib) with either a chemotherapy liposome or another targeted drug (chidamide) for people with peripheral T-cell lymphoma that has come back or stopped responding to treatment. The goal is to see if the combination works better than current options.
This trial tests a new drug called golidocitinib added to standard chemotherapy (CHOP) for people newly diagnosed with certain types of T-cell lymphoma. It aims to see if the combination works better than CHOP alone.
This Phase 3 study compares two chemo options—CHOP alone versus CHOP plus AC—for people whose peripheral T-cell lymphoma is the “T-follicular helper” type (PTCL-TFH). The goal is to see which treatment works better for people who have not received lymphoma treatment yet.
Hear when a new Lymphoma, T-Cell, Peripheral trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.